GlobeNewswire

Telix Pharmaceuticals, INSERM and ARRONAX Enter into Translational Research Partnership

Del

MELBOURNE, Australia and NANTES, France, April 16, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) ("Telix", the "Company"), a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR), has today announced a research partnership with the French National Institute of Health and Medical Research (Institut national de la santé et de la recherche médicale or "INSERM") and the "Accelerator for Research in Radiochemistry and Oncology at Nantes Atlantic" (ARRONAX).

INSERM is a leading translational research organization with a strong track record of industry engagement and technology development to benefit human health. ARRONAX is a unique cyclotron (particle accelerator) facility and a world-leader in the production of certain novel radioactive isotopes, including 211At (astatine). Together, INSERM and ARRONAX have created a highly capable nuclear medicine research cluster in Nantes with a track record of cutting-edge translational research.

Under the research partnership, Telix will explore the feasibility of using several of its clinical targeting agents with astatine. Astatine is an "alpha emitter", a very high-energy radionuclide that is capable of significantly altering the tumour microenvironment when attached to a molecular targeting agent that is specific for cancer cells. The agreement will fund sufficient staff and facility time to conduct a number of studies over a two-year period, including preparation for pilot clinical studies in the nuclear medicine department of University Hospital of Nantes. The agreement also accesses a portfolio of intellectual property that has been developed within the Nantes cluster that may lead to new products and indications for Telix's therapeutic pipeline.

Telix Europe President Ms. Odile Jaume stated, "The Nantes nuclear research cluster is one of the finest translational environments in Europe, with a particular strength and capability in astatine, including production facilities and processes that are capable of making materials for human research. This collaboration has the potential to expand the clinical utility of Telix's technology and build a set of 'next generation' products that may deliver even greater clinical utility to cancer patients."

Professor Michel Chérel (team leader, INSERM University of Nantes) and Dr Jean-Francois Gestin (radiochemistry development) noted, "We are pleased to be working with Telix to progress the use of astatine in a clinical setting. This partnership is a great example of translational research aiming at truly personalized medicine in France and beyond. The clinical translation of astatine therapy will be performed in the nuclear medicine department of Nantes Centre Hospitalier Universitaire (CHU) and l'Institut de Cancérologie de l'Ouest  (ICO) chaired by Professor Françoise Kraeber-Bodéré, in collaboration with the Labex IRON network (Innovative Radiopharmaceuticals in Oncology and Neurology) and "Le SIRIC ILIAD" (Imaging and Longitudinal Investigations to Ameliorate Decision-making in Multiple Myeloma and Breast Cancer)."

Professor Ferid Haddad, Director of ARRONAX added, "Our facility has been established with the development of alpha-nuclide therapy in mind. To this end, this highly innovative partnership with Telix is an important step forward and we believe that it will result in the development of new cancer treatment strategies."

About Telix Pharmaceuticals Limited

Telix Pharmaceuticals Limited (Telix) is a clinical-stage biopharmaceutical company focused on the development of diagnostic and therapeutic products based on targeted radiopharmaceuticals or "molecularly-targeted radiation" (MTR). The company is headquartered in Melbourne with international operations in Brussels (EU), Kyoto (JP) and Indianapolis (US). Telix is developing a portfolio of clinical-stage oncology products that address significant unmet medical need in renal, prostate and brain (glioblastoma) cancer. Telix is listed on the Australian Securities Exchange (ASX:TLX). For more information visit www.telixpharma.com.

About INSERM

INSERM brings together 15,000 researchers, engineers, technicians, and administrative staff around one common goal: to improve the health of all by advancing knowledge of life and disease, innovation in treatment, and public health research. INSERM is the leading European academic biomedical research institution, with nearly 12,000 publications a year. For more information visit www.inserm.fr

About INSERM CRCINA

INSERM CRCINA Oncology Nuclear team is one of the few research groups in France dedicated to radioimmunotherapy (RIT) and, in particular, the development of alpha-nuclide therapy. The CRCINA team has the capability to develop new therapeutics from bench to bedside. For more information visit www.crcina.org

About ARRONAX

The Groupement d'Intérêt Public (GIP) ARRONAX is based in Nantes, France. It research infrastructure dedicated to the production of radioactive materials for nuclear medicine, including sterile production for clinical use. The core of the facility is a 70 MeV multi-particle high intensity cyclotron. ARRONAX routinely produces several innovative radionuclides and is one of the few places worldwide producing ­211At (astatine). For more information visit www.arronax-nantes.fr  

Important Information

This announcement does not constitute an offer to sell, or a solicitation of an offer to buy, securities in the United States, or in any other jurisdiction in which such an offer would be illegal. The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933 (the "US Securities Act"), or under the securities laws of any state or other jurisdiction of the United States and may not be offered or sold within the United States, unless the securities have been registered under the US Securities Act or an exemption from the registration requirements of the US Securities Act is available.

None of the products described in this release have obtained a marketing authorization from the US Food and Drug Administration.

 

         Corporate Contact

Dr Christian Behrenbruch
Telix Pharmaceuticals Limited
CEO
Email: chris@telixpharma.com

Investor and Media Relations

Kyahn Williamson
WE Buchan
Tel: +61 (3) 9866 4722
Email: kwilliamson@buchanwe.com.au



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Telix Pharmaceuticals Limited via Globenewswire

Om GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Følg saker fra GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra GlobeNewswire

Nasdaq, Inc. Prices €600 Million Senior Notes Offering25.3.2019 20:07:00 CETPressemelding

NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (the “Company”) (Nasdaq: NDAQ) today announced that it priced a public offering of €600,000,000 aggregate principal amount of 1.75% senior notes due 2029 (the “Offering”). The Company expects to use the net proceeds from the Offering to refinance indebtedness and for other general corporate purposes. J.P. Morgan Securities plc, Merrill Lynch International, Mizuho International plc and Skandinaviska Enskilda Banken AB (publ) are acting as joint book-running managers for the Offering. HSBC Bank plc, ICBC Standard Bank Plc, Nordea Bank Abp, The Toronto-Dominion Bank and Wells Fargo Securities International Limited are acting as co-managers for the Offering. The Offering is being made pursuant to an effective shelf registration statement, previously filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”). Before investing, you should read the prospectus supplement and accompanying prospectus, as well as oth

‘How to Sell a Massacre’ an Al Jazeera Investigation into Australia’s One Nation Party and Gun Lobby25.3.2019 18:04:00 CETPressemelding

Australia’s One Nation Party Lobbying the National Rifle Association of America (NRA) for Millions of Dollars One Nation’s Chief of Staff, James Ashby, hoped to secure $US20 million political donations to “own the lower house and the upper house” DOHA, Qatar, March 25, 2019 (GLOBE NEWSWIRE) -- A three-year undercover operation by Al Jazeera shows officials from the National Rifle Association of America (NRA) advising delegates from an Australian political party on how to roll back strict gun control laws and how to deal with critics following a mass shooting. Representatives from Pauline Hanson’s One Nation political party were seen seeking millions of dollars in donations from supporters of the U.S. gun lobby in Washington D.C. in order for more guns to flow into Australia. They were coached on how to react if softer gun laws ever led to a mass shooting there. An NRA media liaison officer said the organization remains silent in the immediate aftermath of a multiple shooting, but then

Radient Technologies Inc. Announces Addition of Three Key Members to its Management Team25.3.2019 12:30:00 CETPressemelding

EDMONTON, Alberta, March 25, 2019 (GLOBE NEWSWIRE) -- Radient Technologies Inc. (“Radient” or the “Company”) (TSX Venture: RTI; OTCQX: RDDTF) is pleased to announce that it has appointed Mr. Adrian Marshall and Mr. James Blakelock to the joint role of Executive Vice President, Corporate Strategy and Planning, and Mr. Bill Wasson to the role of Senior Vice President, Capital Markets and Investor Relations. Working closely with Radient’s existing Management Team and Board of Directors, they will be instrumental in developing, driving and communicating the Company’s corporate strategy and global expansion. Denis Taschuk, CEO & President of Radient, commented: “These additions to our management team are very strategic in nature, and we consider ourselves fortunate to have attracted such top talent as we move forward with our global expansion plans. Both Mr. Marshall and Mr. Blakelock bring to Radient decades of experience working directly with some of the world’s leading rapid growth consu

Forterra Announces Rich Hunter as President of Drainage Pipe & Products and Vik Bhatia of Water Pipe & Products Segments25.3.2019 11:00:00 CETPressemelding

IRVING, Texas, March 25, 2019 (GLOBE NEWSWIRE) -- Forterra, Inc. (“Forterra” or the "Company”) (NASDAQ: FRTA), a leading manufacturer of water and drainage pipe and products in the United States and Eastern Canada, today announced the appointment of Rich Hunter as President of its Drainage Pipe & Products (“Drainage”) segment, and Vik Bhatia as President of its Water Pipe & Products (“Water”) segment. In their new roles, Rich and Vik will continue to report to Jeff Bradley, Chief Executive Officer. Hired as Chief Operating Officer in June 2018, Rich has successfully directed the operations team in delivering measurable improvements in cost, productivity and quality. Vik, who joined Forterra in August of 2017, has had several senior leadership roles, most recently providing focused commercial leadership in the development and execution of sales and customer service strategy for Water. Forterra CEO Jeff Bradley commented, “Rich and Vik have proven themselves as strong leaders who are bot

Nasdaq, Inc. Announces Proposed Senior Notes Offering25.3.2019 10:00:00 CETPressemelding

NEW YORK, March 25, 2019 (GLOBE NEWSWIRE) -- Nasdaq, Inc. (the “Company”) (Nasdaq: NDAQ) today announced that it plans to offer, subject to market and other conditions, Euro-denominated senior notes (the “Offering”). The Company expects to use the net proceeds from the Offering to refinance indebtedness and for other general corporate purposes. J.P. Morgan Securities plc, Merrill Lynch International, Mizuho International plc and Skandinaviska Enskilda Banken AB (publ) will act as joint book-running managers for the Offering. HSBC Bank plc, ICBC Standard Bank Plc, Nordea Bank Abp, The Toronto-Dominion Bank and Wells Fargo Securities International Limited are acting as co-managers for the Offering. The Offering will be made pursuant to an effective shelf registration statement, previously filed by the Company with the U.S. Securities and Exchange Commission (the “SEC”). Before investing, you should read the prospectus supplement and accompanying prospectus, as well as other documents the

cPacket Networks Acquires Solarflare’s SolarCapture Appliance Business25.3.2019 10:00:00 CETPressemelding

Joint Solution Provides cPacket Customers with 40Gbps Visibility into High Speed Critical Networks and Retrospective Analysis of Operational and Security Issues SAN JOSE, Calif., March 25, 2019 (GLOBE NEWSWIRE) -- cPacket Networks, a leading provider of next-generation network performance monitoring and packet broker solutions, has entered into an agreement with Solarflare to acquire the company’s SolarCapture® Appliance business. Solarflare’s SolarCapture Appliance business provides network traffic capture capability for a variety of IT NetOps and SecOps applications including compliance, service-level-agreement monitoring, performance monitoring, security analytics, network forensics, and record keeping. Now an integral part of cPacket’s cStor (integrated packet-forensics for advanced real-time-analytics) product-line, the combined solution provides 100-percent lossless capture for speeds up to 40Gbps. “Making the SolarCapture Appliance technology a permanent addition to our cStor pr